Potentiation of Th1-type immune responses to Mycobacterium tuberculosis antigens in mice by cationic liposomes combined with de-O-acylated lipooligosaccharide

Ara Ko, Seo Ri Wui, Ji In Ryu, Yeon Jeong Lee, Do Thi Thu Hien, Inmoo Rhee, SungJae Shin, Shin Ae Park, Kwang Sung Kim, Yang Je Cho, Na Gyong Lee

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. Bacillus Calmette-Guérin (BCG) vaccine is the only TB vaccine currently available, but it is not sufficiently effective in preventing active pulmonary TB or adult infection. With the purpose of developing an improved vaccine against TB that can overcome the limitations of the current BCG vaccine, we investigated whether adjuvant formulations containing de-O-acylated lipooligosaccharide (dLOS) are capable of enhancing the immunogenicity and protective efficacy of TB subunit vaccines. The results revealed that the dLOS/dimethyl dioctadecyl ammonium bromide (DDA) adjuvant formulation significantly increased both humoral and Th1-type cellular responses to TB subunit vaccine that are composed of three antigens, Ag85A, ESAT-6, and HspX. The adjuvanted TB vaccine also effectively induced the Th1-type response in a BCG-primed mouse model, suggesting a potential as a booster vaccine. Finally, the dLOS/ DDA-adjuvanted TB vaccine showed protective efficacy against M. tuberculosis infection in vitro and in vivo. These data indicate that the dLOS/DDA adjuvant enhances the Th1-type immunity and protective efficacy of the TB subunit vaccine, suggesting that it would be a promising adjuvant candidate for the development of a booster vaccine.

Original languageEnglish
Pages (from-to)136-144
Number of pages9
JournalJournal of microbiology and biotechnology
Volume28
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Tuberculosis Vaccines
Liposomes
Subunit Vaccines
Bacillus
BCG Vaccine
Mycobacterium tuberculosis
Vaccines
Mycobacterium Infections
lipid-linked oligosaccharides
Mycobacterium tuberculosis antigens
Pulmonary Tuberculosis
Communicable Diseases
Immunity
Tuberculosis
Antigens
Infection

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Applied Microbiology and Biotechnology

Cite this

Ko, Ara ; Wui, Seo Ri ; Ryu, Ji In ; Lee, Yeon Jeong ; Hien, Do Thi Thu ; Rhee, Inmoo ; Shin, SungJae ; Park, Shin Ae ; Kim, Kwang Sung ; Cho, Yang Je ; Lee, Na Gyong. / Potentiation of Th1-type immune responses to Mycobacterium tuberculosis antigens in mice by cationic liposomes combined with de-O-acylated lipooligosaccharide. In: Journal of microbiology and biotechnology. 2018 ; Vol. 28, No. 1. pp. 136-144.
@article{4aba86d73751487ca6f8540e7b422fd5,
title = "Potentiation of Th1-type immune responses to Mycobacterium tuberculosis antigens in mice by cationic liposomes combined with de-O-acylated lipooligosaccharide",
abstract = "Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. Bacillus Calmette-Gu{\'e}rin (BCG) vaccine is the only TB vaccine currently available, but it is not sufficiently effective in preventing active pulmonary TB or adult infection. With the purpose of developing an improved vaccine against TB that can overcome the limitations of the current BCG vaccine, we investigated whether adjuvant formulations containing de-O-acylated lipooligosaccharide (dLOS) are capable of enhancing the immunogenicity and protective efficacy of TB subunit vaccines. The results revealed that the dLOS/dimethyl dioctadecyl ammonium bromide (DDA) adjuvant formulation significantly increased both humoral and Th1-type cellular responses to TB subunit vaccine that are composed of three antigens, Ag85A, ESAT-6, and HspX. The adjuvanted TB vaccine also effectively induced the Th1-type response in a BCG-primed mouse model, suggesting a potential as a booster vaccine. Finally, the dLOS/ DDA-adjuvanted TB vaccine showed protective efficacy against M. tuberculosis infection in vitro and in vivo. These data indicate that the dLOS/DDA adjuvant enhances the Th1-type immunity and protective efficacy of the TB subunit vaccine, suggesting that it would be a promising adjuvant candidate for the development of a booster vaccine.",
author = "Ara Ko and Wui, {Seo Ri} and Ryu, {Ji In} and Lee, {Yeon Jeong} and Hien, {Do Thi Thu} and Inmoo Rhee and SungJae Shin and Park, {Shin Ae} and Kim, {Kwang Sung} and Cho, {Yang Je} and Lee, {Na Gyong}",
year = "2018",
month = "1",
day = "1",
doi = "10.4014/jmb.1709.09009",
language = "English",
volume = "28",
pages = "136--144",
journal = "Journal of Microbiology and Biotechnology",
issn = "1017-7825",
publisher = "Korean Society for Microbiolog and Biotechnology",
number = "1",

}

Potentiation of Th1-type immune responses to Mycobacterium tuberculosis antigens in mice by cationic liposomes combined with de-O-acylated lipooligosaccharide. / Ko, Ara; Wui, Seo Ri; Ryu, Ji In; Lee, Yeon Jeong; Hien, Do Thi Thu; Rhee, Inmoo; Shin, SungJae; Park, Shin Ae; Kim, Kwang Sung; Cho, Yang Je; Lee, Na Gyong.

In: Journal of microbiology and biotechnology, Vol. 28, No. 1, 01.01.2018, p. 136-144.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Potentiation of Th1-type immune responses to Mycobacterium tuberculosis antigens in mice by cationic liposomes combined with de-O-acylated lipooligosaccharide

AU - Ko, Ara

AU - Wui, Seo Ri

AU - Ryu, Ji In

AU - Lee, Yeon Jeong

AU - Hien, Do Thi Thu

AU - Rhee, Inmoo

AU - Shin, SungJae

AU - Park, Shin Ae

AU - Kim, Kwang Sung

AU - Cho, Yang Je

AU - Lee, Na Gyong

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. Bacillus Calmette-Guérin (BCG) vaccine is the only TB vaccine currently available, but it is not sufficiently effective in preventing active pulmonary TB or adult infection. With the purpose of developing an improved vaccine against TB that can overcome the limitations of the current BCG vaccine, we investigated whether adjuvant formulations containing de-O-acylated lipooligosaccharide (dLOS) are capable of enhancing the immunogenicity and protective efficacy of TB subunit vaccines. The results revealed that the dLOS/dimethyl dioctadecyl ammonium bromide (DDA) adjuvant formulation significantly increased both humoral and Th1-type cellular responses to TB subunit vaccine that are composed of three antigens, Ag85A, ESAT-6, and HspX. The adjuvanted TB vaccine also effectively induced the Th1-type response in a BCG-primed mouse model, suggesting a potential as a booster vaccine. Finally, the dLOS/ DDA-adjuvanted TB vaccine showed protective efficacy against M. tuberculosis infection in vitro and in vivo. These data indicate that the dLOS/DDA adjuvant enhances the Th1-type immunity and protective efficacy of the TB subunit vaccine, suggesting that it would be a promising adjuvant candidate for the development of a booster vaccine.

AB - Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. Bacillus Calmette-Guérin (BCG) vaccine is the only TB vaccine currently available, but it is not sufficiently effective in preventing active pulmonary TB or adult infection. With the purpose of developing an improved vaccine against TB that can overcome the limitations of the current BCG vaccine, we investigated whether adjuvant formulations containing de-O-acylated lipooligosaccharide (dLOS) are capable of enhancing the immunogenicity and protective efficacy of TB subunit vaccines. The results revealed that the dLOS/dimethyl dioctadecyl ammonium bromide (DDA) adjuvant formulation significantly increased both humoral and Th1-type cellular responses to TB subunit vaccine that are composed of three antigens, Ag85A, ESAT-6, and HspX. The adjuvanted TB vaccine also effectively induced the Th1-type response in a BCG-primed mouse model, suggesting a potential as a booster vaccine. Finally, the dLOS/ DDA-adjuvanted TB vaccine showed protective efficacy against M. tuberculosis infection in vitro and in vivo. These data indicate that the dLOS/DDA adjuvant enhances the Th1-type immunity and protective efficacy of the TB subunit vaccine, suggesting that it would be a promising adjuvant candidate for the development of a booster vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85043596735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043596735&partnerID=8YFLogxK

U2 - 10.4014/jmb.1709.09009

DO - 10.4014/jmb.1709.09009

M3 - Article

VL - 28

SP - 136

EP - 144

JO - Journal of Microbiology and Biotechnology

JF - Journal of Microbiology and Biotechnology

SN - 1017-7825

IS - 1

ER -